0000950170-24-009801.txt : 20240201
0000950170-24-009801.hdr.sgml : 20240201
20240201161501
ACCESSION NUMBER: 0000950170-24-009801
CONFORMED SUBMISSION TYPE: 144
PUBLIC DOCUMENT COUNT: 1
FILED AS OF DATE: 20240201
DATE AS OF CHANGE: 20240201
SUBJECT COMPANY:
COMPANY DATA:
COMPANY CONFORMED NAME: Atea Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001593899
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 460574869
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 144
SEC ACT: 1933 Act
SEC FILE NUMBER: 001-39661
FILM NUMBER: 24587102
BUSINESS ADDRESS:
STREET 1: 225 FRANKLIN STREET
STREET 2: SUITE 2100
CITY: BOSTON
STATE: MA
ZIP: 02110
BUSINESS PHONE: 857-204-8109
MAIL ADDRESS:
STREET 1: 225 FRANKLIN STREET
STREET 2: SUITE 2100
CITY: BOSTON
STATE: MA
ZIP: 02110
REPORTING-OWNER:
COMPANY DATA:
COMPANY CONFORMED NAME: Vavricka John
CENTRAL INDEX KEY: 0001829630
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 144
MAIL ADDRESS:
STREET 1: C/O ATEA PHARMACEUTICALS, INC.
STREET 2: 125 SUMMER STREET
CITY: BOSTON
STATE: MA
ZIP: 02110
144
1
primary_doc.xml
144
0001829630
XXXXXXXX
LIVE
0001593899
Atea Pharmaceuticals, Inc.
001-39661
225 Franklin Street
Suite 2100
Boston
MA
02110
857-284-8891
John Vavricka
Chief Commercial Officer
Common Stock
Morgan Stanley
2000 Westchester Ave
Purchase
NY
10577-2530
13552
55156.64
83435513
02/01/2024
NASDAQ
Common Stock
01/31/2024
Shares acquired upon vesting of restricted stock units awarded under Issuer's 2020 Incentive Award Plan
Issuer
N
33334
01/31/2023
Services rendered
Y
02/01/2024
03/25/2022
/s/ John Vavricka